Manuel Muro *

Autor invitado por SIIC

El trabajo muestra que el desarrollo de anticuerpos especificos de alelo puede ser menos infrecuente de loa que se podria presuponer

DESARROLLO DE ANTICUERPOS ANTI-HLA ESPECIFICOS DE ALELO EN TRASPLANTE RENAL

En conclusión, “anticuerpos alelo específicos” podrían no ser infrecuentes y pueden formarse contra únicas sustituciones aminoacidicas. La ocurrencia de “anticuerpos alelo específicos” eleva el asunto de la compatibilidad en trasplante de órganos sólidos, cuando los donantes no son generalmente tipados a nivel alélico

*Manuel Muro
describe para SIIC los aspectos relevantes de su trabajo
SPECIFIC "INTRA-ALLELE" AND "INTRA-BROAD ANTIGEN" HUMAN LEUKOCYTE ANTIGEN ALLOANTIBODIES IN KIDNEY GRAFT TRANSPLANTATION
Institución principal de la investigación
*Servicio de Inmunologia. Hospital Universitario Virgen de la Arrixaca, Murcia, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
[1] Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a
prospective trial. Am J Transplant 2004;4:438–43.
[2] Piazza A, Poggi E, Ozzella G, Borrelli L, Monaco PI, Scornajenghi A, et al. Public
epitope specificity of HLA class I antibodies induced by failed transplant:
alloantibody characterization by flow cytometric techniques. Transplantation
2006;81:1298.
[3] Piazza A, Ozzella G, Poggi E, Gennarelli D, Catalano M, Cremona R, Adorno D.
Intra-broad antigens” and “intra-alleles” HLA alloantibodies. In Terasaki PI
(ed): Visuals of the European Clinical Histocompatibility Workshop: Canoga
Park, CA, 2008.
[4] Muro M, Llorente S, MarÎn L, et al. Acute vascular rejection mediated by HLA
antibodies in a cadaveric kidney recipient: discrepancies between FlowPRATM,
ELISA and CDC vs Luminex screening. Nephr Dial Transpl 2005;20:223–6.
[5] Muro M, Rivera J, Botella C, Campillo JA, Ferrer F,A´ lvarez-Lo´ pez MR. HLA-DR
antibodies in transfusion-related acute lung injury (TRALI): A case report.
Transfus Apher Sci 2008;38:209–12.
[6] Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J, Ozawa M. The
importance of anti-HLA-specific antibody strength in monitoring kidney
transplant patients. Am J Transplant 2007;7:1027–31.
[7] Howell M, Mutunga M, Pengilley R, Carter V. Use of Luminex technology for
identification of HLA class I allele specific antibodies-occurrence and practicalities
for clinical transplantation. In Terasaki PI (ed): Visuals of the European
Clinical Histocompatibility Workshop: Canoga Park, CA, 2008.
[8] Lucas D, Campillo JA, LÔpez-HernÂndez R, MartÎnez-GarcÎa P, LÔpez-SÂnchez
M, Botella C, et al. Allelic diversity of MICA gene and MICA/HLA-b haplotypic
variation in a population of the Murcia region in southeastern Spain. Hum
Immunol 2008;69:655–60.
[9] Elsner HA, DeLuca D, Strub J, Blasczyk R. HistoCheck: rating of HLA class I and II
mismatches by an internet-based software tool. Bone Marrow Transplant
2004;33:165–9.
[10] Duquesnoy RJ, Askar M. HLAMatchmaker: A molecularly based algorithm for
histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and
HLA-DP. Hum Immunol 2007;68:12–25.
[11] Dankers MKA, Witvliet MD, Roelen D, de Lange P, Korfage N, Persijn GG, et al.
The number of aminoacid triplet differences between patient and donor is
predictive for the antibody reactivity against mismatched human leukocyte
antigens. Transplantation 2004;77:1236–9.
[12] Duquesnoy RJ. Human leukocyte antigen class II antibodies and transplant
outcome. Transplantation 2008;86:638–40.
[13] Duquesnoy RJ, Awadalia Y, Lomago J, et al. Retransplant candidates have
donor-specific antibodies that react with structurally defined HLA-DR, DQ, DP
epitopes. Transpl Immunol 2008;18:352–60.
[14] Issa N, Cosio F, Gloor J, Sethi S, Dean PG, Moore SB, et al. Transplant glomerulopathy:
risk and prognosis related to anti-human leukocyte antigen class II
antibody levels. Transplantation 2008;86:681–5.
[15] Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran P. The role of B cells and
alloantibody in the host response to human organ allografts. Immunol Rev
2003;196:197–218.
[16] Muro M, Palacios S, Moya-Quiles MR, Candela M, A´ lvarez-Lo´ pez MR. Acute
haemolytic transfusion reaction secondary to HLA alloimmunization. Int J Lab
Haematol 2008;30:84–6.
[17] Suarez-Alvarez B, LÔpez-VÂzquez A, GonzÂlez MZ, Fdez-Morera JL, DÎaz-Molina B,
Blanco-Gelaz MA, et al. The relationship of anti-MICA antibodies and MICA expression
with heart allograft rejection. Am J Transplant 2007;7:1842–8.
[18] Muro M, Marin L, Miras M, Moya-Quiles R, Minguela A, SÂnchez-Bueno F, et al.
Human liver allograft recipients harbouring anti-donor preformed lymphocytotoxic
antibodies exhibit a poor graft survival at the first year after transplantation.
Experience of one centre. Transpl Immunol 2005;14:91–7.
[19] Marin L, Torio A, Muro M, Fernandez-Parra R, Minguela A, Bosch V, et al.
Alloimmune neonatal neutropenia and thrombocytopenia associated with
maternal anti HNA-1a, HPA-3b and HLA antibodies. Pediatr Allergy Immunol
2005;16:279–82.
[20] El-awar N, Akaza T, Terasaki PI, Nguyen A. Human leukocyte antigen class I
epitope: updated to 103 total epitopes, including C locus. Transplantation
2007;84:532.
[21] Lomago J, Jelenik L, Zern D, Howe J, Martell J, Zeevi A, Duquesnoy RJ. How did a
patient who types for HLA-B*4403 develop antibodies that react with HLAB*
4402? Hum Immunol 2010;71:176–8.

Otros artículos de Manuel Muro

85. López-Hernández R, Valdés M, Lucas D, Salama H, Campillo JA, Martínez-Garcia P, Salgado G, López-Sanchez M, Botella C, Minguela A, Miras M, Álvarez-López MR, Carballo F, Muro M. Association analysis of the MICA gene polymorphism and MICA-129 dymorphism and inflammatory bowel disease susceptibility in a Spanish population. Human Immunol. 2010; 71: 512-514.
83. López-Alvarez R, Moya-Quiles R, Minguela A, Gil J, Miras M, Campillo JÁ, Díaz-Alderete M, García-Alonso A, Sánchez-Bueno F, Vicário JL, Muro M, Álvarez-López MR. HLA-C matching and liver transplants. Donor-recipient genotypes influence early outcome and CD8+KIR2D+ T cells recuperation. Transplantation 2009; 88:S54-61.
79. Muro M, López-Hernández R, Campillo JA, Lucas D, Martínez-García P, Botella C, Minguela A, Alvarez-López R. MICA gene and relevance to immune responses in organ transplants and inflammatory, tumoral and autoimmune diseases. Curr. Immunol. Rev. 2009; 5(2): 161-166.
76. Lucas D, Campillo JA, López-Hernández R, Martínez-Garcia P, López-Sanchez M, Botella C, Salgado G, Minguela A, Álvarez-López MR, Muro M. Allelic diversity of MICA gene and MICA/HLA-B haplotypic variation in a population of the Murcia region in southeastern Spain. Human Immunol 2008; 69: 655-660.
70. Muro M, Palacios S, Moya-Quiles MR, Candela M, Álvarez-López MR. Acute haemolytic transfusion reaction secondary to HLA alloimmunization. Int. Jnl. Lab. Haematol. 2008; 30: 84-86.
71. Muro M, Marin L, Torio A, Pagan JA, Álvarez-López MR. CCL5/RANTES chemokine polymorphisms are not associated with atopic and nonatopic asthma in a Spanish population. Int. J. Immunogenetics. 2008; 35: 19-23.
72. Muro M, Rojas G, Botella C, Miras M, Campillo JA, Minguela A, Sánchez-Bueno F, Bermejo J, Ramirez P, Álvarez-López MR. CT60A/G marker of the 3´-UTR of CTLA-4 gene and liver transplant. Transplant Immunol. 2008; 18(3): 246-249.
73. Muro M, Rivera J, Botella C, Campillo JA, Ferrer F, Álvarez-López MR. HLA-DR antibodies in Transfusion-Related Acute Lung Injury (TRALI): A case report. Transfus. Apher. Sci. 2008; 38: 209-212.
65. Suarez-Alvarez B, López-Vazquez A, González MZ, Fdez-Morera JL, Diaz-Molina B, Blanco-Gelaz MA, Pascual D, Martinez-Borra J, Muro M, Álvarez-López MR, López-Larrea C. The relatioship of Anti-MICA antibodies and MICA expression with heart allograft rejection. Am. J. Transplant. 2007; 7(7): 1842-1848.
63. Muro M, Llorente S, Gonzalez-Soriano MJ, Minguela A, Gimeno L, Álvarez-López MR. Pre-formed Donor-Specific Alloantibodies (DSA) detected only by Luminex technology using HLA-coated microspheres and causing acute humoral rejection and kidney graft dysfunction. En: Clinical Transplans 2006. Terasaki PI (ed). Los Angeles, CA, 2007; p. 379-383.

Para comunicarse con Manuel Muro mencionar a SIIC como referencia:

---

Acerca del trabajo completo

DESARROLLO DE ANTICUERPOS ANTI-HLA ESPECIFICOS DE ALELO EN TRASPLANTE RENAL

Título original en castellano
ALOANTICUERPOS HLA “INTRA-ALELO” (IA) E “INTRA-ANTIGENO” (IBA) EN TRASPLANTE DE INJERTO DE RIÑON

Autor
Manuel Muro¹
1 Medico, Servicio de Inmunologia. Hospital Universitario Virgen de la Arrixaca, Murcia, España, Staff Immunologist

Acceso a la fuente original
Human Immunology
http://www.elsevier.com/locate/humimm

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades